Abstract: The disclosure relates to the treatment of blindness due to age-related presbyopia, age-related macular degeneration (AMD), diabetic retinopathy (DR) and/or diabetic macular edema (DME) in a human or animal. Age-related presbyopia is the loss of accommodation in any individual more than 40-50 years old, currently treated by reading glasses. AMD is the most common cause of irreversible loss of sight in persons >65 years in the western world. At this time, no treatment is available for the dry form of AMD. The dry form of AMD is characterized by vision threatening Drüsen, which are (sub)retinal accumulations of advanced glycation end products (AGEs) and fluorophores. DR and DME are the most common cause of irreversible loss of sight in persons <65 years in the western world. Current therapies for age-related presbyopia, AMD, DR and DME are disappointing and do not prevent the evolution to vision impairment, atrophy or blindness.

Abstract: A method and system are provided for measuring post-translational modification of proteins in a subject. The method comprises recording of infrared radiation within a predetermined wavenumber range and attenuated by an integument of the subject, such that the integument is still attached to the subject. The method further comprises the step of comparing the attenuation of infrared radiation to a predetermined value for deriving information regarding post-translational modification of proteins in the integument.

Abstract: This disclosure relates to the application of the enzyme fructosyl-amino acid oxidase (FAOD)—without the addition of proteases—in medical and cosmetical conditions that are characterized by the presence of advanced glycation end products (AGEs). More specifically, this disclosure relates to the treatment of eye diseases in humans or animals. AGEs accumulate in the aging eye causing presbyopia, cataract, dry eyes, age-related macular degeneration, glaucoma and diabetic retinopathy. Hence, the disclosure relates to the application of FAOD in order to deglycate and inactivate the AGEs.

Abstract: A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods.

Abstract: The disclosure relates to the treatment of blindness due to age-related presbyopia, age-related macular degeneration (AMD), diabetic retinopathy (DR) and/or diabetic macular edema (DME) in a human or animal. Age-related presbyopia is the loss of accommodation in any individual more than 40-50 years old, currently treated by reading glasses. AMD is the most common cause of irreversible loss of sight in persons>65 years in the western world. At this time, no treatment is available for the dry form of AMD. The dry form of AMD is characterized by vision threatening Drüsen, which are (sub)retinal accumulations of advanced glycation end products (AGEs) and fluorophores. DR and DME are the most common cause of irreversible loss of sight in persons<65 years in the western world. Current therapies for age-related presbyopia, AMD, DR and DME are disappointing and do not prevent the evolution to vision impairment, atrophy or blindness.

Abstract: A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods.

Abstract: A method and system are provided for measuring post-translational modification of proteins in a subject. The method comprises recording of infrared radiation within a predetermined wavenumber range and attenuated by an integument of the subject, such that the integument is still attached to the subject. The method further comprises the step of comparing the attenuation of infrared radiation to a predetermined value for deriving information regarding post-translational modification of proteins in the integument.

Abstract: The invention relates to a method for monitoring renal disease in a subject, comprising subjecting a sample comprising albumin from that subject to electrophoresis, preferably capillary electrophoresis, wherein carbamylated albumin is used as a bio-marker for the monitoring of the renal disease, which is preferably achieved by measuring the symmetry of the albumin peak in the assay. The invention further comprises the use of capillary electrophoresis for determining the amount of carbamylated albumin. Also claimed is a system for the determination of carbamylated serum albumin.